Advertisement

Rheumatology International

, Volume 39, Issue 2, pp 395–398 | Cite as

How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol

  • Vicenç Torrente-SegarraEmail author
  • Manuel Fernandez Prada
  • Rosa Expósito Moliner
  • Noemí Patricia Garrido Puñal
  • Amalia Sánchez-Andrade Fernández
  • José Ramón Lamua Riazuelo
  • Alejandro Olivé
  • Juan Víctor Tovar Beltrán
  • RENACER Study Group (REgistro NAcional CERtolizumab)
Correspondence

Dear Editor,

Several tumor necrosis factor inhibitors (TNFi) have been released in the last two decades for the treatment of rheumatoid arthritis (RA). The efficacy and safety of Certolizumab pegol (CZP), a PEGilated TNFi, is well established, as reported in randomized clinical trials (RCT) [1, 2]. Around 30% of RA patients are within the age range of 65 years or older, however, they are usually excluded from the RCTs. Elderly patients associate a declining of immune cell function and have increased risk of adverse drug reaction, infection and a higher rate of comorbidities that may influence immunosupressant treatment decisions [3, 4, 5]. Thus, scant data on both safety and effectiveness of biological disease modifying drugs (bDMARD) in clinical practice in elderly population is currently available [6]. The aim of this study was to determine the effectiveness, safety and survival of CZP in elderly-onset RA patients (EORA) in a real world setting at 12-month follow-up and compared it...

Keywords

Rheumatoid arthritis Tumor necrosis factor inhibitors Safety Effectiveness 

Notes

Acknowledgements

RENACER Study Group (REgistro NAcional CERtolizumab): José Antonio González Ferrández, Carmen Moragues Pastor, Ana Urruticoechea Arana, José Rey Rey, Raúl Veiga Cabello, Ángel Aragón Díez, Noelia Vázquez Fuentes, Anna Martínez Cristóbal, Mª del Pilar Navarro Alonso, Sergi Ordoñez Palau, Alejandro Muñoz Jiménez, José Miguel Ruiz Martín, Asuncion Acosta Pereira, Ángel María García Aparicio, Jesús Carlos Fernández, Mercedes Morcillo, Emilio Giner Serret, Nuria Montala Palau, Carlos Rodríguez Escalera, José Campos Esteban, Juan José de Agustín de Oro, Pedro Giralt Celiméndiz, Desireé Ruiz Vílchez, Silvia Paredes González-Albo, Laura Garrido Courel, Carmen Olga Sánchez González, Maria del Pilar Ahijado Guzmán, Patricia Castro Pérez, Rosa Garcia Portales, Julia Fernández Melón, Gabriel Mercadal Orfila, José Raúl Noguera Pons, Concepción Moll Tuduri, Mª Dolores García Armario, Víctor Eliseo Quevedo Vila, Juan José Lerma Garrido, Antonio Gracia Pérez, Elena Aurrecoechea Aguinaga, Amalia Rueda Cid, Marina Soledad Moreno García, Eduardo Loza Cortina, Delia Taverner Torrent, Rebeca Belmonte Gómez, María Jesús Martínez Blasco, Raúl Moreno Domínguez, Jenaro Graña Gil, Raúl Cortés Verdú, Mª Teresa Ruiz Jimeno, Cristina Mata Arnaiz, Georgina Salvador Alarcón, Ana María Fernández Ortiz, Marco Moreno Zazo, Susana Barona Trapote, Manuel Utrilla Utrilla, Jaime Calvo Alén, César Antonio Egües Dubuc, Azucena Hernández Sanz, Mar López-Sidro Ibáñez, César Díaz Torne, Vicente Aldasoro Cáceres, Vera Ortiz Santamaría, Mª Ángeles Hernández del Río, Leticia del Olmo Pérez, Jesús Quijada Carrera, Claudia Stoye, Mª de los Ángeles Belmonte, Mª Ángeles Acosta Mérida, Carlos Tomás Roura, Arantxa Conesa Mateos, Joan Dalmau Carolà and José María Salazar Vallinas.

Funding

This study have not received any funding.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study has been approved by the relevant local ethics committee (Internal Code 13/34) of the Hospital General Hospitalet-Moisès Broggi (Hospitalet Llobregat, Spain).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

296_2018_4205_MOESM1_ESM.doc (50 kb)
Supplementary material 1 (DOC 50 KB)

References

  1. 1.
    Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P et al (2014) Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis 73:2094–2100CrossRefGoogle Scholar
  2. 2.
    Keystone E, Heijde D, Mason D Jr, Landewe´ R, Vollenhoven RV, Combe B et al (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58:3319–3329CrossRefGoogle Scholar
  3. 3.
    Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C (2007) Physicians of the Swiss clinical quality management program for rheumatoid arthritis. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 57:679–685CrossRefGoogle Scholar
  4. 4.
    Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316–1322CrossRefGoogle Scholar
  5. 5.
    Murota A, Kaneko Y, Yamaoka K, Takeuchi T (2016) Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol 43:1984–1988CrossRefGoogle Scholar
  6. 6.
    Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L (2018) Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 36:29–35Google Scholar
  7. 7.
    Tornero Molina J, Sanmartí Sala R, Rodríguez Valverde V, Martín Mola E, Marenco de la Fuente JL, González Álvaro I, Muñoz Fernández S, Gómez-Reino Carnota J, Carreño Pérez L, Batlle Gualda E, Balsa Criado A, Andreu JL, Alvaro-Gracia JM, Martínez López JA, Loza Santamaría E (2010) Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol Clin 6:23–36CrossRefGoogle Scholar
  8. 8.
    Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, Tavernier C, Maillefert JF (2005) Survival and safety of treatment with infliximab in the elderly population. Rheumatology 44:695–696CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Vicenç Torrente-Segarra
    • 1
    Email author
  • Manuel Fernandez Prada
    • 2
  • Rosa Expósito Moliner
    • 3
  • Noemí Patricia Garrido Puñal
    • 4
  • Amalia Sánchez-Andrade Fernández
    • 5
  • José Ramón Lamua Riazuelo
    • 6
  • Alejandro Olivé
    • 7
  • Juan Víctor Tovar Beltrán
    • 8
  • RENACER Study Group (REgistro NAcional CERtolizumab)
  1. 1.Rheumatology DepartmentHospital General Hospitalet-Sant Joan Despí Moisès BroggiHospitalet LlobregatSpain
  2. 2.Rheumatology DepartmentHospital Universitario de GuadalajaraGuadalajaraSpain
  3. 3.Rheumatology DepartmentHospital Comarcal LaredoLaredoSpain
  4. 4.Rheumatology DepartmentHospital Universitario Virgen del RocíoSevillaSpain
  5. 5.Rheumatology DepartmentComplejo Hospital Universitario Lucus AugustiLugoSpain
  6. 6.Rheumatology DepartmentHospital Universitario de HenaresAlcalá de HenaresSpain
  7. 7.Rheumatology DepartmentHospital Germans Tries i PujolBadalonaSpain
  8. 8.Rheumatology DepartmentHospital General Universitario de ElcheElcheSpain

Personalised recommendations